DiaCarta Obtains Exclusive License for Non-Invasive Early Detection Colon Cancer Test
DIACARTA INC. (“DIACARTA”) and UNIVERSITY OF POTSDAM (Germany) today announced that the parties have entered into an exclusive license agreement for the development and commercialization of non-invasive early detection of colon cancer from stool samples. University of Potsdam holds awarded patent “Method for Conducting Non-Invasive Early Detection of Colon Cancer/or of Colon Cancer Precursor Cells.” Under the terms of the agreement, DiaCarta will pay Potsdam an upfront payment plus additional payments based upon achievement of commercial milestones. DiaCarta will have exclusive rights to develop and commercialize the test globally.
Some key clinical groundwork has been established by the group to develop the non-invasive diagnostic test that could be used to screen for early colorectal cancer as well as precursor lesions by detecting cancer-initiating mutations associated with colorectal cancer, which was published in Cancer Prevention Research.
“DiaCarta’s XNA Clamping technology to block all the WT-DNA is the most promising tool for the non-invasive early detection of mutations, including from liquid biopsy,” said Dr. Bettina Scholtka, assistant professor at the University of Potsdam and inventor of the patent. “We are very pleased to partner with DiaCarta to accelerate worldwide development and commercialization of Non-Invasive Early Detection of Colon Cancer.”
“With this agreement, DiaCarta now can extend its QClamp® somatic mutation test product line targeting this unmet market,” said Aiguo Zhang, PhD, DiaCarta’s Founder and CEO. “We look forward to working with Dr. Bettina Scholtka and her team at University of Potsdam to move the unique colon cancer early detection program forward as quickly as possible.”
About DiaCarta Inc.
DiaCarta, is an innovative translational genomics and precision molecular diagnostics company located in the San Francisco Bay Area. QClamp® is a rapid, sensitive qPCR based platform for detection of somatic mutations in cancer genes. The technology can also used for mutant DNA enrichment for Sanger and NGS sequencing. HPV QuantiVirus® cervical and head-neck cancer tests are based on branched DNA technology, which allow detection of oncogenic E6/E7 mRNAs from 14 high-risk subtypes and genotyping of HPV 16 and 18, directly from samples without RNA purification and RT-PCR.
DiaCarta announced that it is launching a new suite of CE-IVD marked highly sensitive hydrolysis probe (TaqMan-qPCR) based QClamp® assays for detection of common cancer mutations in genes, such as KRAS, NRAS, BRAF, EGFR, PIK3CA and JAK2, using tissue biopsy (FFPE) and liquid biopsy (cfDNA) samples.
DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test
DIACARTA, Inc. announced today that it has received a $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to continue development of its RadTox™ cfDNA radiation therapy toxicity monitoring test kit for cancer patients.
DiaCarta has been recognized as one of the Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 by Med Tech Outlook Magazine. The positioning is based on an evaluation of DiaCarta’s specialty in genomic testing for biomarkers, personalized diagnostics and clinical sample testing service provided in their CLIA-certified lab.
DiaCarta today announced that it has signed a distribution agreement with Arrow Diagnostics. Under the agreement, Arrow Diagnostics becomes sole distributor of ColoScape™ a multigene biomarker TaqMan qPCR in vitro diagnostic (CE-IVD) test in Italy, San Marino & Vatican City.
CIO Applications has chosen DiaCarta as one of the Top 25 Life Sciences Technology Vendors 2018. The positioning is based on an evaluation of DiaCarta’s specialty in personalized diagnostics, translational genomics and clinical sample testing services provided in both US and China.